CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE
Clinical trials for CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE explained in plain language.
Never miss a new study
Get alerted when new CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE trials appear
Sign up with your email to follow new studies for CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to halt early blood cancers before they progress
Disease control Recruiting nowThis study tests a pill called olutasidenib in people with certain early blood disorders (CCUS, lower-risk MDS, or CMML) that have a specific gene change (IDH1 mutation). The goal is to see if the drug can control the disease and improve blood counts. Fifteen participants will re…
Matched conditions: CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:38 UTC
-
Could early treatment stop a Pre-Cancer blood condition?
Disease control Recruiting nowThis study looks at whether giving an oral drug early to people with a high-risk blood condition called CCUS is safe and practical. CCUS can sometimes turn into blood cancer, and currently there is no standard treatment. Participants can choose to take the drug or just be watched…
Matched conditions: CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE
Phase: EARLY_PHASE1 • Sponsor: Lachelle D. Weeks, MD, PhD • Aim: Disease control
Last updated May 17, 2026 04:32 UTC
-
Vitamin c boost: could high doses make chemo work better for tough blood cancers?
Disease control Recruiting nowThis study tests whether adding high-dose vitamin C to standard chemotherapy can help treat blood cancers like lymphoma and chronic myelomonocytic leukemia (CMML) that have returned or not responded to treatment. About 80 adults will receive the combination therapy. The goal is t…
Matched conditions: CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 04:18 UTC
-
Cholesterol drug may slow blood cancer progression in early study
Disease control Recruiting nowThis study tests whether statins, a common cholesterol-lowering drug, can reduce inflammation and slow the worsening of two blood disorders: CCUS and lower-risk MDS. These conditions can progress to more serious blood cancers, and there are no approved treatments to improve survi…
Matched conditions: CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New drug targets gene mutation to boost blood counts in rare blood disorder
Disease control Recruiting nowThis study tests whether enasidenib, a drug that blocks a faulty protein from a mutated IDH2 gene, can safely improve blood cell counts in people with clonal cytopenia of undetermined significance (CCUS). About 15 adults with unexplained low blood counts for at least 6 months and…
Matched conditions: CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
Can a single drug stop blood cancer before it starts?
Prevention Recruiting nowThis study tests whether the drug canakinumab can prevent blood cancer in people with a condition called CCUS, where blood counts are low and there are genetic changes that raise cancer risk. The drug works by reducing inflammation, which may be a trigger for cancer. About 110 ad…
Matched conditions: CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE
Phase: PHASE2 • Sponsor: Uma Borate • Aim: Prevention
Last updated May 13, 2026 16:02 UTC
-
Turmeric compound tested for blood disorder symptoms
Symptom relief Recruiting nowThis study tests whether a curcumin supplement can reduce inflammation and improve symptoms in people with certain blood disorders, including CCUS, low-risk MDS, and MPNs. The trial will enroll 30 participants who will receive either curcumin or a placebo for 12 months. Researche…
Matched conditions: CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Symptom relief
Last updated May 15, 2026 11:54 UTC
-
Can a simple genetic test catch blood cancers before they start?
Knowledge-focused Recruiting nowThis study uses advanced genetic testing (next generation sequencing) to look for early warning signs of pre-myeloid cancers and bone marrow failure in 2000 people. Participants have certain blood abnormalities or genetic markers that may increase their risk. The goal is to bette…
Matched conditions: CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE
Phase: NA • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated May 17, 2026 04:41 UTC
-
Can we predict blood cancer after ovarian cancer treatment?
Knowledge-focused Recruiting nowThis study aims to understand why some people who have had ovarian or other solid cancers later develop blood cancers. Researchers will follow 2,000 participants to identify genetic and environmental risk factors. The goal is to improve monitoring and prevention for cancer surviv…
Matched conditions: CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE
Sponsor: University of Washington • Aim: Knowledge-focused
Last updated May 17, 2026 04:34 UTC
-
10-Year study tracks hidden DNA changes that raise risk of blood cancer and heart disease
Knowledge-focused Recruiting nowThis study follows 306 adults with certain DNA changes in their blood cells (called CHIP or CCUS) to see how these changes affect health over time. Researchers will track whether participants develop blood cancers, heart disease, or other conditions. Participants give blood and u…
Matched conditions: CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated May 11, 2026 20:39 UTC